USD
$0.00
(0.00%
)At Close (As of Sep 12, 2025)
$1.34B
Market Cap
-
P/E Ratio
-0.56
EPS
$5.82
52 Week High
$1.89
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$68M |
Total Revenue | $29M |
Cost Of Revenue | $97M |
Costof Goods And Services Sold | $97M |
Operating Income | -$315M |
Selling General And Administrative | $73M |
Research And Development | $167M |
Operating Expenses | $247M |
Investment Income Net | - |
Net Interest Income | $38M |
Interest Income | $38M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $97M |
Income Before Tax | -$200M |
Income Tax Expense | -$38M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$163M |
Comprehensive Income Net Of Tax | - |
Ebit | -$301M |
Ebitda | -$204M |
Net Income | -$163M |
Field | Value (USD) |
---|---|
Total Assets | $1.4B |
Total Current Assets | $751M |
Cash And Cash Equivalents At Carrying Value | $156M |
Cash And Short Term Investments | $156M |
Inventory | - |
Current Net Receivables | $92M |
Total Non Current Assets | $609M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $42M |
Intangible Assets Excluding Goodwill | $42M |
Goodwill | $48M |
Investments | - |
Long Term Investments | $82M |
Short Term Investments | $469M |
Other Current Assets | $34M |
Other Non Current Assets | - |
Total Liabilities | $304M |
Total Current Liabilities | $77M |
Current Accounts Payable | $34M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $4.6M |
Total Non Current Liabilities | $228M |
Capital Lease Obligations | $65M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $65M |
Other Current Liabilities | $16M |
Other Non Current Liabilities | $1.5M |
Total Shareholder Equity | $1.1B |
Treasury Stock | - |
Retained Earnings | $117M |
Common Stock | $777M |
Common Stock Shares Outstanding | $294M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$109M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $97M |
Capital Expenditures | $78M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $121M |
Cashflow From Financing | $13M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$163M |
Field | Value (USD) |
---|---|
Gross Profit | -$68M |
Total Revenue | $29M |
Cost Of Revenue | $97M |
Costof Goods And Services Sold | $97M |
Operating Income | -$315M |
Selling General And Administrative | $73M |
Research And Development | $167M |
Operating Expenses | $247M |
Investment Income Net | - |
Net Interest Income | $38M |
Interest Income | $38M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $97M |
Income Before Tax | -$200M |
Income Tax Expense | -$38M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$163M |
Comprehensive Income Net Of Tax | - |
Ebit | -$301M |
Ebitda | -$204M |
Net Income | -$163M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.